Pfizer's unsuccessful takeover of AstraZeneca Case Study

Pfizers unsuccessful takeover of AstraZeneca - Case Study ExampleIn this regard, it is necessary to expect a brief knowledge about AstraZeneca. The company is a United Kingdom (UK) based pharmaceutical company headquartered in London. AstraZeneca is also recognised among outgo companies in the global pharmaceutical industry. Like Pfizer, this company also have significant experience in acquisition and optical fusions as it has acquired and collaborated with a number of companies in recent years.The case in this paper focuses on the failed merger between Pfizer and AstraZeneca which took place in May, 2014. It was collected from the Guardian (2014a) that the chairman of Pfizer initially approached chairman of AstraZeneca regarding merger in November 2013 while the detailed backchat took place in January, 2014. The exploratory meeting between both the companies took place in New York on January 5, 2014. It was gathered that Pfizer declare oneselfed a settlement payment of 58 bill ion or 46.61 per share in its preliminary proposal to AstraZeneca. The offer also included establishment of a new holding company listed and headquartered in the US. However, AstraZenecas board turned down the offer concluding that Pfizer has heavily undervalued the company and its prospects. The company also questioned proceeding structure and offered inversion structure of Pfizer and ultimately the proposal ended by the mid of January 2014 (International Business Times, 2014 The Telegraph, 2014 The Guardian, 2014a 2014b).On 26 April 2014, Pfizer contacted chairman of AstraZeneca for a new discussion regarding collaboration of both the companies but AstraZeneca declined this offer. Consequently, Pfizer publicised its interest in merger with AstraZeneca on 28 April 2014. The US pharmaceutical giant revealed that they are planning to offer AstraZeneca cash and share at an attractive premium. They further added that they would move company domicile